Optimizing antiepileptic drug treatment in tumoral epilepsy

Epilepsia

Volumn 54, Issue SUPPL. 9, 2013, Pages 97-104

  Perucca, Emilio ^a,b  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptic drugs; Brain tumor; Medical treatment; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT;

BRAIN NEOPLASMS; COMPLICATION; EPILEPSY; HUMAN; ANTIEPILEPTIC DRUGS; BRAIN TUMOR; REVIEW; SEIZURE; THERAPY;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; EPILEPSY; HUMANS;

ANTIEPILEPTIC DRUGS; BRAIN TUMOR; MEDICAL TREATMENT; SEIZURES;

EID: 84894363620     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12452     Document Type: Article

References (52)

1. Algharabil J, Kintner DB, Wang Q, Begum G, Clark PA, Yang SS, Lin SH, Kahle KT, Kuo JS, Sun D. (2012) Inhibition of Na(+)-K(+)-2Cl (-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells. Cell Physiol Biochem 30:33-48.
2. Anderson GD, Lin YX, Berge C, Ojemann GA. (1997) Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 87:252-256.
3. Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD. (2010) Levetiracetam enhances p53- mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 12:917-927.
4. Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. (2001) Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 12:217-219.
5. Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, Sontheimer H. (2011) Glutamate release by primary brain tumors induces epileptic activity. Nat Med 17:1269-1274.
6. Cannizzaro E, Albisetti M, Wohlrab G, Schmugge M. (2007) Severe bleeding complications during antiepileptic treatment with valproic acid in children. Neuropediatrics 38:42-45.
7. Chang BS, Lowenstein DH, Quality Standards Subcommittee of the American Academy of Neurology. (2003) Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 60:10-16.
8. Conti L, Palma E, Roseti C, Lauro C, Cipriani R, de Groot M, Aronica E, Limatola C. (2011) Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex. Epilepsia 52:1635-1644.
9. Das RR, Artsy E, Hurwitz S, Wen PY, Black P, Golby A, Dworetzky B, Lee JW. (2012) Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas. J Neurooncol 107:565-570.
10. De Groot M, Aronica E, Heimans JJ, Reijneveld JC. (2011) Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology 77:532-539.
11. De Groot M, Reijneveld JC, Aronica E, Heimans JJ. (2012) Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. Brain 135(Pt 4):1002-1016.
12. Felix FH, de Araujo OL, da Trindade KM, Trompieri NM, Fontenele JB. (2013) Survival of children with malignant brain tumors receiving valproate: a retrospective study. Childs Nerv Syst 29:195-197.
13. French JA. (2006) Hepatic enzyme induction: it does really matter. Epilepsy Curr 6:38-39.
14. Gerstner T, Teich M, Bell N, Longin E, Dempfle CE, Brand J, König S. (2006) Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 47:1136-1143.
15. Gilioli I, Vignoli A, Visani E, Casazza M, Canafoglia L, Chiesa V, Gardella E, La Briola F, Panzica F, Avanzini G, Canevini MP, Franceschetti S, Binelli S. (2012) Focal epilepsies in adult patients attending two epilepsy centers: classification of drug-resistance, assessment of risk factors, and usefulness of "new" antiepileptic drugs. Epilepsia 53:733-740.
16. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG. (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54:1886-1893.
17. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. (2006) Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 80:83-90.
18. Haas BR, Sontheimer H. (2010) Inhibition of the sodium-potassiumchloride cotransporter isoform-1 reduces glioma invasion. Cancer Res 70:5597-5606.
19. Hildebrand J, Lecaille C, Perennes J, Delattre JY. (2005) Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 65:212-215.
20. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJ. (2002) Effect of radiotherapy and other treatmentrelated factors on mid-term to long-term cognitive sequelae in lowgrade gliomas: a comparative study. Lancet 360:1361-1368.
21. Jaeckle KA, Ballman K, Furth A, Buckner JC. (2009) Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 73:1207-1213.
22. Kahlenberg CA, Fadul CE, Roberts DW, Thadani VM, Bujarski KA, Scott RC, Jobst BC. (2012) Seizure prognosis of patients with low grade tumors. Seizure 21:540-545.
23. Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, Vecht CJ. (2013) Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 15:961-967.
24. Kim LG, Johnson TL, Marson AG, Chadwick DW, MRC MESS Study group. (2006) Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 5:317-322.
25. Khan RB, Onar A. (2006) Seizure recurrence and risk factors after antiepilepsy drug withdrawal in children with brain tumors. Epilepsia 47:375-379.
26. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801-1811.
27. Lwu S, Hamilton MG, Forsyth PA, Cairncross JG, Parney IF. (2010) Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience. J Neurooncol 96:403-408.
28. Maschio M. (2012) Brain tumor-related epilepsy. Curr Neuropharmacol 10:124-133.
29. Micali G, Linthicum K, Han N, West DP. (1999) Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Pharmacotherapy 19:223-227.
30. Mohanraj R, Brodie MJ. (2005) Outcomes in newly diagnosed localization-related epilepsies. Seizure 14:318-323.
31. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52:717-724.
32. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255-260.
33. Osuka S, Takano S, Watanabe S, Ishikawa E, Yamamoto T, Matsumura A. (2012) Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain. Neurol Med Chir (Tokyo) 52:186-193.
34. Perucca E. (2006) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246-255.
35. Perucca E, Tomson T. (2011) The pharmacological treatment of epilepsy in adults. Lancet Neurol 10:446-456.
36. Psaras T, Will BE, Schoeber W, Rona S, Mittelbronn M, Honegger JB. (2008) Quantitative assessment of postoperative blood collection in brain tumor surgery under valproate medication. Zentralbl Neurochir 69:165-169.
37. Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R, Illmer T, Wang Y, Hosius C, Nikolova Z, Bornhäuser M, Dresemann G. (2008) Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 3:198-203.
38. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE II, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359-9368.
39. Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, Schuetz EG, Evans WE. (2000) Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356:285-290.
40. Rossetti AO, Stupp R. (2010) Epilepsy in brain tumor patients. Curr Opin Neurol 23:603-609.
41. Rudà R, Bello L, Duffau H, Soffietti R. (2012) Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol 14(Suppl. 4):iv55-iv64.
42. Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B, Cavalcanti D, Baulac M. (1998) Is the underlying cause of epilepsy a major prognostic factor for recurrence' Neurology 51:1256-1262.
43. Sherman JH, Moldovan K, Yeoh HK, Starke RM, Pouratian N, Shaffrey ME, Schiff D. (2011) Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. Neurosurgery 114:1617-1621.
44. Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. (2004) Seizure prophylaxis in patients with brain tumors: a metaanalysis. Mayo Clin Proc 79:1489-1494.
45. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W, European Federation of Neurological Societies. (2010) Guidelines on management of lowgrade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124-1133.
46. Sontheimer H, Bridges RJ. (2012) Sulfasalazine for brain cancer fits. Expert Opin Investig Drugs 21:575-578.
47. Temkin NR. (2001) Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: Meta-analysis of controlled trials. Epilepsia 42:515-524.
48. Van Breemen MS, Wilms EB, Vecht CJ. (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421-430.
49. Ward MM, Barbaro NM, Laxer KD, Rampil IJ. (1996) Preoperative valproate administration does not increase blood loss during temporal lobectomy. Epilepsia 37:98-101.
50. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R. (2011) Prolonged survival with valproic acid use in the EORTC/ NCIC temozolomide trial for glioblastoma. Neurology 77:1156-1164.
51. Weller M, Stupp R, Wick W. (2012) Epilepsy meets cancer: when, why, and what to do about it' Lancet Oncol 13:e375-e382.
52. You G, Sha Z, Jiang T. (2012) The pathogenesis of tumor-related epilepsy and its implications for clinical treatment. Seizure 21:153-159.